- active not recruitingPHASE1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
This study is looking into a new medication called ALTA2618 for adults with certain advanced cancers that have a specific genetic change (AKT1 E17K mutation). The main goal is to check its safety and find the right dose.
United States · Australia · France - recruitingPHASE1
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
This study tests an investigational drug called PhOx430 for advanced cancers that haven't responded to other treatments. It aims to find a safe dose and see how well it works, especially in certain types of solid tumours.
France · Italy - active not recruitingNA
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
This study looks for specific gene changes (NTRK, ROS1, ALK fusions) in soft tissue sarcomas. We check tumour samples for these changes using special tests. Finding these changes helps us guide patients to suitable treatments, potentially including a drug called entrectinib.
France - recruitingPHASE3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This study looks into new ways to treat advanced stomach and gut cancers called GIST. It compares a new drug called CGT9486 (bezuclastinib) combined with an existing drug, sunitinib, against sunitinib alone, to see which works better for patients who haven't responded well to other treatments.
United States · Argentina · Australia - active not recruitingPHASE1
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
This study looks at a new drug, RP-6306, combined with standard medicines (carboplatin and paclitaxel) for advanced ovarian or womb (uterine) cancer. We want to find the safest dose and see how well it works, especially for cancers with a specific gene change called TP53.
Canada - recruitingPHASE1
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
This study is testing a new drug called IPH5301 for advanced cancers like breast, stomach, and lung. It's a first-time-in-human study, meaning it's the very first time this drug is being given to people. Researchers want to find a safe dose, either alone or with other treatments.
France - active not recruitingPHASE2
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
This study looks at a new drug called avelumab for men with advanced penile cancer. It's for those who can't have standard chemotherapy or for whom it has stopped working. We want to see if avelumab can help shrink their tumours.
Canada - recruiting
Immune Resistance Interrogation Study
This study looks at why some cancers stop responding to immunotherapy. We collect tumour samples, blood, and stool from patients who had immunotherapy to understand how their bodies react differently.
Canada - recruitingPHASE3
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
This study offers continued access to a cancer treatment for patients who are already benefiting from it in previous trials. It aims to check the long-term safety and effectiveness of the medication for people with advanced or metastatic cancer.
United States · Australia · Belgium - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - active not recruitingPHASE2
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
This study looks at new treatments (ramucirumab or merestinib) combined with standard chemotherapy for people with advanced biliary tract cancer. It aims to see how well these new drug combinations work and if they are safe.
United States · Argentina · Australia - active not recruitingPHASE1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
This study is testing a new drug, IDRX-42, for people with advanced gastrointestinal stromal tumors (GIST). It's the first time this drug is being used in humans. We want to see if it's safe, how the body handles it, and if it helps shrink tumors.
United States · Belgium · China - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain